Lee Financial’s Pacific Biosciences PACB Stock Holding History

Lee Financial’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-28	Closed	-$1K	–	903
2021 Q4	$1K	Buy	+28	New	+$676	﹤0.01%	860

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Lee Financial's PACB Position: Q1 2022 in Review

Lee Financial sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 28 shares — an estimated $1K sold.

Lee Financial first reported a position in PACB in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

Lee Financial reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
Lee Financial sold 28 Pacific Biosciences shares in Q1 2022, an estimated $1K.
Lee Financial first reported a position in Pacific Biosciences in Q4 2021 and held it in 1 quarter.
Lee Financial's Pacific Biosciences position peaked at $1K in Q4 2021.
250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on Lee Financial's 13F filing for Q1 2022, filed 11 May 2022.